Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CARM1 | Q86X55 | 2/20 | 0.64 |
| ▸ | PRMT6 | Q96LA8 | 2/20 | 0.64 |
| ▸ | LTA4H | P09960 | 1/20 | 0.54 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.54 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.51 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.51 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.51 |
| ▸ | ACHE | P22303 | 1/20 | 0.50 |
| ▸ | BCHE | P06276 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14944847 | 0.85 | CARM1 (0.53) | CARM1PRMT6LTA4HEPHX2SLC6A3 | |
| SCHEMBL25740924 | 0.84 | SLC6A3 (0.57) | CARM1PRMT6SLC6A3SIGMAR1ACHE | |
| SCHEMBL7248339 | 0.82 | CARM1 (0.70) | CARM1PRMT6SLC6A3SIGMAR1BCHE | |
| Bromide SCHEMBL7247812 | 0.81 | CARM1 (0.68) | CARM1PRMT6SLC6A3SIGMAR1BCHE | |
| SCHEMBL12929 | 0.78 | ACHE (0.66) | SLC6A3SIGMAR1ACHE | |
| SCHEMBL11205656 | 0.78 | ACHE (0.66) | SLC6A3SIGMAR1ACHE | |
| SCHEMBL12725 | 0.78 | ACHE (0.66) | SLC6A3SIGMAR1ACHE | |
| SCHEMBL18420781 | 0.78 | LTA4H (0.55) | LTA4HEPHX2SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL11022506 | 0.78 | CCR3 (0.56) | CARM1PRMT6LTA4HACHE | |
| SCHEMBL4923829 | 0.77 | CXCR4 (0.61) | CARM1PRMT6L3MBTL1ACHEBCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8871789-B2 | Method of preventing or treating viral infection | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2014-10-28 | — | — | US | disclosed |
| US-20130123344-A1 | METHOD OF PREVENTING OR TREATING VIRAL INFECTION | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2013-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123344-A1 | METHOD OF PREVENTING OR TREATING VIRAL INFECTION | KDM1B, KDM1A, KDM2A | CARM1 44/4885PRMT6 50/4885LTA4H 1909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.